A Metabolomics Study of Retrospective Forensic Data from Whole Blood Samples of Humans Exposed to 3,4-Methylenedioxymethamphetamine: A New Approach for Identifying Drug Metabolites and Changes in Metabolism Related to Drug Consumption

Journal of Proteome Research

Volumn 15, Issue 2, 2016, Pages 619-627

  Nielsen, Kirstine L ^a   Telving, Rasmus ^a   Andreasen, Mette F ^a   Hasselstrøm, Jørgen B ^a   Johannsen, Mogens ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

3,4 methylenedioxymethamphetamine (MDMA); acylcarnitine; ecstasy; metabolism; metabolomics; S adenosyl l homocysteine; thiomorpholine 3 carboxylate; tryptophan; UPLC HR TOFMS

Indexed keywords

2 OCTENOYLCARNITINE; 3 CARBOXYLATE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 9 DECENOYLCARNITINE; ACYLCARNITINE; ADENOSINE; ADENOSINE PHOSPHATE; ADENOSYLHOMOCYSTEINASE; DRUG METABOLITE; GLYCEROL; INOSINE; LYSOPHOSPATIDYLCHOLINE; THIOMORPHOLINE; TRYPTOPHAN; UNCLASSIFIED DRUG; URIC ACID; MIDOMAFETAMINE;

ARTICLE; BLOOD SAMPLING; DRUG USE; HUMAN; METABOLOMICS; NEUROTOXICITY; PRIORITY JOURNAL; BLOOD; FORENSIC TOXICOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

CHROMATOGRAPHY, LIQUID; FORENSIC TOXICOLOGY; HUMANS; MASS SPECTROMETRY; METABOLOMICS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION;

EID: 84957685061     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/acs.jproteome.5b01023     Document Type: Article

References (42)

1. de la Torre, R.; Farre, M.; Roset, P. N.; Pizarro, N.; Abanades, S. Et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition Ther. Drug Monit. 2004, 26 (2) 137-144 10.1097/00007691-200404000-00009
2. Capela, J. P.; Carmo, H.; Remiao, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview Mol. Neurobiol. 2009, 39 (3) 210-271 10.1007/s12035-009-8064-1
3. Kalant, H. H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs Can. Med. Assoc. J. 2001, 165 (7) 917-928
4. Maurer, H. H. On the Metabolism and the Toxicological Analysis of Methylenedioxyphenylalkylamine Designer Drugs by Gas Chromatography-Mass Spectrometry Ther. Drug Monit. 1996, 18 (4) 465-470 10.1097/00007691-199608000-00027
5. Schwaninger, A. E.; Meyer, M. R.; Barnes, A. J.; Kolbrich-Spargo, E. A.; Gorelick, D. A.; Goodwin, R. S.; Huestis, M. A.; Maurer, H. H. Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration Clin. Chem. 2011, 57 (12) 1748-1756 10.1373/clinchem.2011.172254
6. Jones, D. C.; Duvauchelle, C.; Ikegami, A.; Olsen, C. M.; Lau, S. S.; de la Torre, R.; Monks, T. J. Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat Brain J. Pharmacol. Exp. Ther. 2004, 313 (1) 422-431 10.1124/jpet.104.077628
7. Erives, G. V.; Lau, S. S.; Monks, T. J. Accumulation of Neurotoxic Thioether Metabolites of 3,4-Methylenedioxymethamphetamine in Rat Brain J. Pharmacol. Exp. Ther. 2007, 324 (1) 284-291 10.1124/jpet.107.128785
8. Ramaley, C.; Leonard, S. C.; Miller, J. D.; Wilson, D. T.-M.; Chang, S. Y.; Chen, Q.; Li, F.; Du, C. In Vitro Metabolism of 3,4-Methylenedioxymethamphetamine in Human Hepatocytes J. Anal. Toxicol. 2014, 38 (5) 249-255 10.1093/jat/bku023
9. Zaitsu, K.; Miyawaki, I.; Bando, K.; Horie, H.; Shima, N. Metabolic profiling of urine and blood plasma in rat models of drug addiction on the basis of morphine, methamphetamine, and cocaine-induced conditioned place preference Anal. Bioanal. Chem. 2014, 406 (5) 1339-1354
10. Dinis-Oliveira, R. J. Metabolomics of drugs of abuse: a more realistic view of the toxicological complexity Bioanalysis 2014, 6 (23) 3155-3159 10.4155/bio.14.260
11. Perrine, S.; Michaels, M. S.; Ghoddoussi, F.; Hyde, E. M.; Tancer, M. E. Et al. Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat NMR Biomed. 2009, 22 (4) 419-425 10.1002/nbm.1352
12. Shima, N.; Miyawaki, I.; Bando, K.; Horie, H.; Zaitsu, K.; Katagi, M.; Bamba, T.; Tsuchihashi, H.; Fukusaki, E. Influences of methamphetamine-induced acute intoxication on urinary and plasma metabolic profiles in the rat Toxicology 2011, 287 (1-3) 29-37 10.1016/j.tox.2011.05.012
13. Andreasen, M. F.; Telving, R.; Rosendal, I.; Eg, M. B.; Hasselstrøm, J. B.; Andersen, L. V. A fatal poisoning involving 25C-NBOMe Forensic Sci. Int. 2015, 251, e1-e8 10.1016/j.forsciint.2015.03.012
14. Sørensen, L. K.; Hasselstrøm, J. B. A high-throughput multi-class liquid chromatography tandem mass spectrometry method for quantitative determination of licit and illicit drugs in whole blood Anal. Methods 2013, 5 (13) 3185-3193 10.1039/c3ay40443a
15. Smith, C. A.; Want, E. J.; O'Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and Identification Anal. Chem. 2006, 78 (3) 779-787 10.1021/ac051437y
16. Tautenhahn, R.; Böttcher, C.; Neumann, S. Highly sensitive feature detection for high resolution LC/MS BMC Bioinf. 2008, 9 (1) 504 10.1186/1471-2105-9-504
17. Prince, J. T.; Marcotte, E. M. Chromatographic Alignment of ESI-LC-MS Proteomics Data Sets by Ordered Bijective Interpolated Warping Anal. Chem. 2006, 78 (17) 6140-6152 10.1021/ac0605344
18. Kuhl, C.; Tautenhahn, R.; Böttcher, C.; Larson, T. R.; Neumann, S. CAMERA: An Integrated Strategy for Compound Spectra Extraction and Annotation of Liquid Chromatography/Mass Spectrometry Data Sets Anal. Chem. 2012, 84 (1) 283-289 10.1021/ac202450g
19. Sysi-Aho, M.; Katajamaa, M.; Yetukuri, L.; Oresic, M. Normalization method for metabolomics data using optimal selection of multiple internal standards BMC Bioinf. 2007, 8 (1) 93 10.1186/1471-2105-8-93
20. De Livera, A. M.; Bowne, J. B. Analysis of Metabolomics Data, R package version 0.1.4., 2014.
21. Jones, O. A. H.; Spurgeon, D. J.; Svendsen, C.; Griffin, J. L. A metabolomics based approach to assessing the toxicity of the polyaromatic hydrocarbon pyrene to the earthworm Lumbricus rubellus Chemosphere 2008, 71 (3) 601-609 10.1016/j.chemosphere.2007.08.056
22. Friedman, J.; Hastie, T.; Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent J. Stat. Softw. 2010, 33 (1) 1-22 10.18637/jss.v033.i01
23. Väremo, L.; Gatto, F.; Nielsen, J. Kiwi: a tool for integration and visualization of network topology and gene-set analysis BMC Bioinf. 2014, 15 (1) 408 10.1186/s12859-014-0408-9
24. Steuer, A.; Schmidhauser, C.; Schmid, Y.; Rickli, A.; Liechti, M. E.; Kraemer, T. Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and its Phase I and II Metabolites following Controlled MDMA Administration to Humans Drug Metab. Dispos. 2015, 43, 1864 10.1124/dmd.115.066340
25. Lim, H. K.; Foltz, R. L. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: Identification of metabolites using an ion trap detector Chem. Res. Toxicol. 1988, 1 (6) 370-378 10.1021/tx00006a008
26. Aitchison, K. J.; Tsapakis, E. M.; Huezo-Diaz, P.; Kerwin, R. W.; Forsling, M. L.; Wolff, K. Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT J. Psychopharmacol. 2012, 26 (3) 408-418 10.1177/0269881111434624
27. Yang, J.; Jamei, M.; Heydari, A.; Yeo, K. R.; de la Torre, R.; Farré, M.; Tucker, G. T.; Rostami-Hodjegan, A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA J. Psychopharmacol. 2006, 20 (6) 842-849 10.1177/0269881106065907
28. Green, A. R.; Mechan, A. O.; Elliott, J. M.; O'Shea, E.; Colado, M. I. The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Pharmacol. Rev. 2003, 55 (3) 463-508 10.1124/pr.55.3.3
29. Yubero-Lahoz, S.; Ayestas, M. A., Jr.; Blough, B. E.; Partilla, J. S.; Rothman, R. B.; de la Torre, R.; Baumann, M. H. Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain Eur. J. Pharmacol. 2012, 674 (2-3) 337-344 10.1016/j.ejphar.2011.10.033
30. Bartlett, K.; Eaton, S. Mitochondrial beta-oxidation Eur. J. Biochem. 2004, 271 (3) 462-469 10.1046/j.1432-1033.2003.03947.x
31. Millington, D. S.; Stevens, R. D. Acylcarnitines: analysis in plasma and whole blood using tandem mass spectrometry. In Metabolic Profiling Methods and Protocols, Metz, T. O., Ed.; Humana Press Inc: New York, 2011; pp 55-72.
32. Hoppel, C. L.; Genuth, S. M. Carnitine metabolism in normal-weight and obese human subjects during fasting Am. J. Physiol. 1980, 238 (5) E409-E415
33. Costa, C. C. G.; De Almeida, I. T.; Jakobs, C.; Poll-The, B.-T.; Duran, M. Dynamic Changes of Plasma Acylcarnitine Levels Induced by Fasting and Sunflower Oil Challenge Test in Children Pediatr. Res. 1999, 46 (4) 440 10.1203/00006450-199910000-00013
34. Lehmann, R.; Zhao, X.; Weigert, C.; Simon, P.; Fehrenbach, E.; Fritsche, J.; Machann, J.; Schick, F.; Wang, J.; Hoene, M.; Schleicher, E. D.; Häring, H. U.; Xu, G.; Niess, A. M. Medium Chain Acylcarnitines Dominate the Metabolite Pattern in Humans under Moderate Intensity Exercise and Support Lipid Oxidation PLoS One 2010, 5 (7) e11519 10.1371/journal.pone.0011519
35. Virmani, A.; Gaetani, F.; Imam, S.; Binienda, Z.; Ali, S. Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity Ann. N. Y. Acad. Sci. 2003, 993, 197-207 10.1111/j.1749-6632.2003.tb07530.x
36. Alves, E.; Binienda, Z.; Carvalho, F.; Alves, C. J.; Fernandes, E.; de Lourdes Bastos, M.; Tavares, M. A.; Summavielle, T. Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain Neuroscience 2009, 158 (2) 514-523 10.1016/j.neuroscience.2008.10.041
37. Skulachev, V. P. Cytochrome c in the apoptotic and antioxidant cascades FEBS Lett. 1998, 423 (3) 275-280 10.1016/S0014-5793(98)00061-1
38. Shintani-Ishida, K.; Saka, K.; Yamaguchi, K.; Hayashida, M.; Nagai, H.; Takemura, G.; Yoshida, K. i. MDMA induces cardiac contractile dysfunction through autophagy upregulation and lysosome destabilization in rats Biochim. Biophys. Acta, Mol. Basis Dis. 2014, 1842 (5) 691-700 10.1016/j.bbadis.2014.01.013
39. Rozas, C.; Loyola, S.; Ugarte, G.; Zeise, M. L.; Reyes-Parada, M.; Pancetti, F.; Rojas, P.; Morales, B. Acutely applied MDMA enhances long-term potentiation in rat hippocampus involving D1/D5 and 5-HT2 receptors through a polysynaptic mechanism Eur. Neuropsychopharmacol. 2012, 22 (8) 584-595 10.1016/j.euroneuro.2011.11.010
40. Matarese, R. M.; Solinas, S. P.; Montefoschi, G.; Ricci, G.; Cavallini, D. Identification of 1,4-thiomorpholine-3-carboxylic acid (TMA) in normal human urine FEBS Lett. 1989, 250 (1) 75-77 10.1016/0014-5793(89)80688-X
41. Downey, L. A.; Loftis, J. M. Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine Eur. J. Pharmacol. 2014, 727, 125-129 10.1016/j.ejphar.2014.01.032
42. Zhu, B. T. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis Histol. Histopathol. 2002, 17 (4) 1283-1291